Abstract

Fast disintegrating tablets of lorazepam were prepared by effervescent method with a view to enhance patient compliance. A 32 full factorial design was applied to investigate the combined effect of two formulation variables: amount of crospovidone and mixture of sodium bicarbonate, citric acid and tartaric acid (effervescent material) on in vitro dispersion time. Crospovidone (2-8% w/w) was used as superdisintegrant and mixture of sodium bicarbonate, citric acid and tartaric acid (6-18% w/w) was used as effervescent material, along with directly compressible mannitol to enhance mouth feel. The tablets were evaluated for hardness, friability, thickness, drug content uniformity and in vitro dispersion time. Based on in vitro dispersion time (approximately 13 s); the formulation containing 8% w/w crospovidone and 18% w/w mixture of sodium bicarbonate, citric acid and tartaric acid was found to be promising and tested for in vitro drug release pattern (in pH 6.8 phosphate buffer), short-term stability and drug-excipient interaction. Surface response plots are presented to graphically represent the effect of independent variables (concentrations of crospovidone and effervescent material) on the in vitro dispersion time. The validity of the generated mathematical model was tested by preparing two extra-design check point formulations. The optimized tablet formulation was compared with conventional marketed tablet for drug release profiles. This formulation showed nearly eleven-fold faster drug release (t50% 2.8 min) compared to the conventional commercial tablet formulation (t50% >30 min). Short-term stability studies on the formulation indicated that there were no significant changes in drug content and in vitro dispersion time (P<0.05).

Highlights

  • Fast disintegrating tablets of lorazepam were prepared by effervescent method with a view to enhance patient compliance

  • Buffering prevents gastric acids from interacting with drugs themselves, which can be a major cause of stomach and esophageal upsets, (e) they retain their palatability after lengthy storage; they produce fizzy tablets, which may have better consumer appeal than the traditional dosage forms, (f) excellent stability that is inherent to effervescent formulations, surpassing liquid forms, (g) drugs delivered using effervescent technology have predictable and reproducible pharmacokinetic profiles that are more consistent than tablets or capsules, (h) effervescent components aid in improving the therapeutic profiles of active ingredients

  • Where -1=9.0 mg of NaHCO3 and 9.0 mg citric acid and tartaric acid, 0=18.0 mg of NaHCO3 and 18.0 mg citric acid and tartaric acid +1=12 mg of NaHCO3 and 12 mg citric acid and tartaric acid (X2 is the amount of effervescent materials). -0.5= 5.25 mg (X1 is the amount of crospovidone and 13.5 mg of NaHCO3 and 13.5 mg of citric acid + tartaric acid (X2 is the amount of effervescent material) +0.5=9.75 mg (X1 is the amount of crospovidone) and 22.5 mg of NaHCO3 and 22.5 mg citric acid and tartaric acid (X2 is the amount of effervescent material) weighed tablets were placed in a plastic chambered friabilator attached to a motor revolving at a speed of 25 rpm for 4 min

Read more

Summary

MATERIALS AND METHODS

Lorazepam and crospovidone (CP) were gift samples from Centaur Chemicals Pvt. Ltd., Chickboli, India, and Wockhardt Research Centre, Aurangabad, India, respectively. Compressible mannitol (Pearlitol SD200), sodium stearyl fumarate (SSF) were generous gifts from Strides Arco Labs, Bangalore, Glenmark Ltd., Nashik and Alkem Labs Pvt Ltd, Mumbai, India. Mannitol, pineapple flavour, aspartame and cros-povidone were accurately weighed and sifted through sieve No 44. Sodium bicarbonate and anhydrous citric acid and tartaric acid were pre-heated at a temperature of 80o to remove absorbed/ residual moisture and were thoroughly mixed in a mortar to get a uniform powder and added to other ingredients. The ingredients after sifting through sieve No 44 were thoroughly mixed in geometrical order. The blend obtained was directly compressed at 8 mm size to get a tablet of 150 mg weight

Sodium stearyl fumarate
Variable levels in coded In vitro dispersion form*
Weight variation
RESULTS AND DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call